Chart-Typ:
Zeitraum:
| Johnson & Johnson Reports Strong Long-Term Results For ICOTYDE In Plaque Psoriasis | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced new 52-week Phase 3 data from the ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies evaluating ICOTYDE (icotrokinra) in moderate-to-severe... ► Artikel lesen |
| Johnson & Johnson: ICOTYDE (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once-daily pill for plaque psoriasis | Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies
Nearly 60% of... ► Artikel lesen |
| J&J Says DARZALEX SC Granted EU Approval For First Self-Administered Oncology Treatment | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted approval... ► Artikel lesen |
| Biogen Inc.: Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity | In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear... ► Artikel lesen |
| Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics | WESTON (dpa-AFX) - Shares of Alteogen Inc. (196170.KQ) gained around 6 percent on Thursday's trading in South Korea after the biopharma company announced that it has entered into an exclusive... ► Artikel lesen |
| Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen |
| EU Approves DAWNZERA For Hereditary Angioedema, Says Ionis And Otsuka | TOKYO (dpa-AFX) - Ionis Pharmaceuticals, Inc. (IONS) and Otsuka Pharmaceutical Co., Ltd. on Wednesday said the European Commission has approved Dawnzera to prevent repeated attacks of hereditary... ► Artikel lesen |
| Ionis Pharmaceuticals, Inc.: DAWNZERA (donidalorsen) approved in the European Union for hereditary angioedema (HAE) | Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission (EC) has approved DAWNZERA (donidalorsen) in the European Union... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BG MEDICINE INC finden Sie auf Wallstreet Online.